SKF-89,145

SKF-89,145 is a drug that is used in scientific research. It acts as a dopamine agonist and has selective activity at the D1 and D5 subtypes. SKF-89,145 has been used to study the role of these receptors in the brain, and has been shown to produce locomotor stimulation in animals, suggesting potential applications in the treatment of Parkinson's disease and Schizophrenia.

Pharmacology

SKF-89,145 is a dopamine agonist, meaning it activates dopamine receptors in the brain. It has selective activity at the D1 and D5 subtypes, which are primarily found in the striatum and prefrontal cortex.

The activation of these receptors by SKF-89,145 leads to an increase in intracellular signaling and neurotransmission, which can result in a variety of effects depending on the specific brain region and the type of neurons involved.

Clinical significance

The selective activity of SKF-89,145 at D1 and D5 receptors makes it a useful tool for studying the role of these receptors in the brain. For example, it has been used in research to investigate the effects of D1/D5 receptor activation on cognitive processes such as memory and attention.

In addition, SKF-89,145 has been shown to produce locomotor stimulation in animals, suggesting potential applications in the treatment of Parkinson's disease. This is because Parkinson's disease is characterized by a loss of dopamine neurons in the striatum, leading to a decrease in D1 receptor activation and a resulting impairment in motor function.

Furthermore, the ability of SKF-89,145 to activate D1/D5 receptors may also have implications for the treatment of Schizophrenia. This is because schizophrenia is thought to involve a dysfunction in dopamine neurotransmission, particularly in the prefrontal cortex.

See also

• Dopamine receptor D1
• Dopamine receptor D5
• Dopamine agonist
• Parkinson's disease
• Schizophrenia

SKF-89,145 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia